Business Strategies
The Digital Pathology Divide
With two $100 million-plus financings this year, investment in digital pathology is surging, largely driven by the technology’s potential to identify tissue-based biomarkers for precision medicine. But initial use cases are limited and clinical uptake of the technology by hospitals and reference labs has been slow. What will impel them to adopt this technology to a greater extent? By Rachel Laing, Sophie Peltre, and Marie Kerisit, Bionest Partners, and Mark Ratner.
Read Article